Aggressive Resection - A Treatment Option in Patients with Advanced Neuroendocrine Tumors Abstract #2954

Introduction: Different treatment modalities have been considered for patients with malignant advanced neuroendocrine tumors(NETs) of the pancreas and duodenum.Aggressive surgery remains a controversial yet an efficacious antitumor therapy.
Aim(s): For improving survival rate in patients with advanced NETs,wide resection can be performed with acceptable morbidity and mortality rates.
Materials and methods: Patients with advanced NETs who underwent surgery between 2016 to 2019 were enrolled from Sir Ganga Ram Hospital,Jinnah Hospital Lahore.Surgical procedure, pathologic characteristics, mortality rates, and disease-free and overall survival rates were recorded.Disease-free survival was defined as no tumor identified on radiological imaging studies and no detectable abnormal hormone levels.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Surgical treatment and Ablative Therapies
Presenting Author: Doctor Azka Athar
Authors: Athar A

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2935 Prior Surgical Resection and Ga-68-DOTANOC PET/CT Imaging-Based Parameters: Do These Impact Outcomes in Grade II Gastroentero-Pancreatic Neuroendocrine Tumors (GEP-NETs)
Introduction: Grade 2 GEP-NETs have inherent tumor heterogeneity seen with positive expression of somatostatin (SSTR) and glucose (GLUT) receptors. Prior surgical resection and imaging parameters on Ga-68 DOTANOC PET/C are well-established variable impacting prognosis in well-differentiated grade 1 NETs. Since the degree of differentiation is variable in Grade 2 NETs, these parameters have not been studied.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: Dr Ameya Puranik
#1861 Surgical Strategies and Selection Criteria for Patients with Liver Metastasis from Neuroendocrine Tumors: Personal Experience.
Introduction: The role of surgical treatment of liver metastasis from neuroendocrine neoplasm(NET) is still a debated issue,and the management of these patients is entrusted to the practical experience of single centers.The main problem is that there are not available randomized trials comparing surgical resection to unthreated patients or other liver directed therapy.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Surgical treatment
Presenting Author: Dr Bruno Pauletti
#1873 Meta-Analysis of Liver Resection versus Nonsurgical Treatments for Pancreatic Neuroendocrine Tumors with Liver Metastases
Introduction: Available data comparing the efficacy of different treatment regiments are rarely found. No meta-analyses have compared live resection with other nonsurgical treatments in resectable liver metastases from pNETs.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Surgical treatment
Presenting Author: Chunhui Yuan
Authors: Yuan C, ...
#2926 O-Positive Blood Group Is Associated with Prolonged Recurrence-Free Survival Following Pancreatic Neuroendocrine Tumor (PanNET) Curative-Intent Surgical Resection
Introduction: The ABO blood group may influence the development and progression of cancer. In particular, the prognosis of pancreatic adenocarcinoma is better in patients with blood group O. This has not been extensively explored in PanNET.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Dr Louis de Mestier
#1878 Measurement in Blood of a Circulating NET mRNA Gene to Predict Surgical Efficacy
Introduction: Surgery is the only curative treatment for GEP-NETs, but identifying post-surgery residual disease is difficult and often delayed.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Surgical treatment
Presenting Author: Professor Mark Kidd
Keywords: NETest, surgery, biomarker, NET